To help clinicians and patients determine if antibodies protect against reinfection, the ACP discussed tests for diagnosing and estimating the prevalence of COVID-19.
Researchers assessed the risk for severe COVID-19 in patients with microscopic colitis vs the general population.
Researchers conducted serum metabolomic analysis to see if ApoB:ApoA1 ratio is an accurate biomarker of cardiovascular disease risk in patients with juvenile systemic lupus erythematosus.
A team of researchers has developed the severe COVID-19 adaptive risk predictor (SCARP) calculator that reliably predicts the risk of progression to severe disease or death.
Treatment with tocilizumab did not lead to improvement in clinical status and did not lower mortality at 28 days compared with placebo in hospitalized patients with severe pneumonia related to COVID-19.
Indoor mold exposure and the presence of anti-Aspergillus antibodies may be linked to worsened lung function during exacerbations in COPD.
A study designed to evaluate the impact of coronavirus disease 2019 lockdown on people living with type 1 diabetes, shows patients were able to improve their glycemic control indices.
In this narrative review, the researchers examine the potential for neuropathic pain that develops weeks to months after COVID-19.
Treatment with trimethoprim-sulfamethoxazole was associated with improvements in lung function and decreased visits to the emergency department among children with asthma.
Researchers evaluated a case study detailing a teenager who developed severe encephalopathy associated with COVID-19.
